CD8A and neoplasm: Our CD107a+ threshold for tumor reactivity captured T cells with a broad range of activated phenotypes, with CD8+ BT21-reactive TCRs killing significantly more BT21 cells in bulk culture xCELLigence assays (Extended Data Fig. 5).